$57 Million is the total value of Knoll Capital Management, LLC's 17 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SYN | Sell | Synthetic Biologics Inc. | $1,553,000 | -76.5% | 2,034,949 | -45.5% | 2.72% | -76.5% |
| NLNK | Sell | Newlink Genetics Corp | $962,000 | -36.0% | 93,533 | -8.7% | 1.69% | -36.0% |
| OHRP | Sell | OHR Pharmaceutical Inc | $306,000 | -46.1% | 204,137 | -0.4% | 0.54% | -46.1% |
| ORPN | Sell | Bio Blast Pharma Ltd | $214,000 | -49.5% | 206,054 | -17.9% | 0.38% | -49.5% |
| CSBR | Exit | Champions Oncology INC | $0 | – | -111,111 | -100.0% | -0.32% | – |
| CLBS | Exit | Caladrius Biosciences Inc | $0 | – | -55,781 | -100.0% | -0.47% | – |
| Exit | Advaxis Inc.w exp 07/15/201 | $0 | – | -112,500 | -100.0% | -1.32% | – | |
| Exit | Advaxis Inc. | $0 | – | -275,000 | -100.0% | -5.01% | – | |
| CEMP | Exit | Cempra Inc | $0 | – | -180,800 | -100.0% | -7.57% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.